2022-502600-79-00招募中2 期
INCMGA 0012-204: An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204)
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- Incyte Corp.
- 入组人数
- 88
- 试验地点
- 24
- 主要终点
- Group A (INCMGA00012 monotherapy): ORR, defined as the proportion of participants having a CR or PR according to RECIST v1.1, will be determined by ICR.
研究概览
简要总结
To evaluate antitumor activity of INCMGA00012 in Group A
研究设计
- 分配方式
- Na
- 主要目的
- Receiving INCMGA00012 after initial disease progression
- 盲法
- None
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Ability to comprehend and willingness to sign a written ICF for the study
- •Group D only: Tumor tissue tested locally or centrally, based on CLIA certified (or similar certification) laboratory assays, as having FGFR1-3 fusions or rearrangements characterized as follows: a. FGFR1-3 in-frame fusions, b. any FGFR2 rearrangement, or c. FGFR1-3 rearrangement with known partner. Note: See Appendix C for most detailed information on FGFR fusions and/or rearrangements allowed.
- •Group E only:Tumor tissue centrally tested as PD-L1–positive using Ventana SP263 assay (determined based on PD-L1 staining of TCs, ICs, and ICPs and tested as MSS locally or centrally using PCR assay. Microsatellite stability results obtained locally would need to be subsequently confirmed centrally after participant's enrolment.
- •Willing to provide tumor tissue sample (fresh or archived).
- •ECOG performance status 0 to
- •Willingness to avoid pregnancy based on the criteria below. a. Women of childbearing potential must have a negative serum pregnancy test at screening and must agree to take appropriate precautions to avoid pregnancy (with at least 99% certainty) from screening through 6 months after the last dose of study treatment and must refrain from donating oocytes during this period. Permitted methods that are at least 99% effective in preventing pregnancy should be communicated to the participants and their understanding confirmed (See Appendix A). b. Women of nonchildbearing potential (ie, surgically sterile with a hysterectomy and/or bilateral oophorectomy
- •Group F only: Tumor tissue tested as MSI-H centrally or locally using PCR assay. MSI H results obtained locally would need to be subsequently confirmed centrally after participant's enrollment.
- •Must have at least 1 measurable tumor lesion per RECIST v1.
- •Note: Lesions to be used as measurable disease for the purpose of response assessment must either a) not reside in a field that has been subjected to prior radiotherapy, or b) have demonstrated clear evidence of radiographic progression since the completion of prior radiotherapy and prior to study enrollment.
- •Women 18 years of age or older (or as applicable per local country requirements).
- •Histologically confirmed diagnosis of advanced or metastatic endometrial cancer with disease progression on or after treatment with at least 1 platinum-containing regimen for advanced or metastatic disease. Note: for Group E only: No more than 1 systemic regimen for advanced or metastatic disease is allowed. For all groups neoadjuvant chemotherapy in an early disease stage is allowable. Prior hormonal therapy is allowable in any disease setting.
- •Groups A, B and E: Have not been previously treated with a PD-(L)1 inhibitor.
- •Group F only: Radiological evidence of disease progression on or after prior PD (L)1 therapy. Participant must have received at least 2 doses of prior PD-(L)1 therapy. Participant may have received PD-(L)1 therapy either alone or in combination. Disease progression must have occurred on or after the first on treatment scan and must have been confirmed subsequently by imaging ≥ 4 weeks after evidence of initial disease progression. Note: baseline scan within the study may serve as a confirmatory scan for progressive disease. Participant may have achieved objective response (CR or PR) to prior PD-(L)1 therapy followed by disease recurrence.
- •Group A only: Tumor tissue centrally tested as MSI-H using Promega OncoMate™ MSI Dx assay. See Section 8.1.2.1 for assay details.
- •Group B only: Tumor tissue centrally tested as dMMR using MMR IHC assay or known to have ultra-mutated POLE tumor per locally available result. See Section 8.1.2.1 for assay details. Note: POLE ultra-mutated participants need to have documented POLE exonuclease domain mutation (residues 268-471) known to have damaging effect on exonuclease domain function. Test type (eg, PCR or NGS) should be documented in the EDC.
排除标准
- •Groups A,B and E only: Histologically confirmed diagnosis of carcinosarcoma of the uterus.
- •Has an active autoimmune disease requiring systemic immunosuppression with corticosteroids (> 10 mg/day of prednisone or equivalent) or immunosuppressive drugs within 14 days before the first dose of study treatment.
- •Receiving chronic systemic corticosteroids(> 10 mg/day of prednisone or equivalent).
- •Active infections requiring systemic antibiotics or antifungal or antiviral treatment (except where warranted as per Exclusion Criteria 17 and 26) within 7 days before first dose of study treatment.
- •History of organ transplant, including allogeneic stem cell transplantation.
- •Receiving probiotics as of the first dose of study treatment.
- •Known active CNS metastases and/or carcinomatous meningitis.
- •Known additional malignancy that is progressing or requires active treatment, or history of other malignancy within 2 years of study entry with the exception of cured basal cell or squamous cell carcinoma of the skin, superficial bladder cancer, carcinoma in situ of the cervix, or other noninvasive or indolent malignancy, or cancers from which the participant has been disease-free for > 1 year, after treatment with curative intent.
- •Has known active hepatitis B or C (defined as follows) or HIV, HBV, HCV, or HDV coinfection.
- •Known hypersensitivity to any of the study drugs, excipients, or another monoclonal antibody that cannot be controlled with standard measures (eg, antihistamines and corticosteroids).
- •Participants with impaired cardiac function or clinically significant cardiac disease.
- •Histologically confirmed diagnosis of sarcoma of the uterus.
- •Women who are pregnant or breast-feeding.
- •If participant received major surgery, then they must have recovered adequately from toxicities and/or complications from the intervention before starting study treatment.
- •Has received a live vaccine within 28 days of the planned start of study treatment.
- •Evidence of interstitial lung disease or active, noninfectious pneumonitis.
- •Current use of prohibited medication as noted in Section 6.8.
- •Any condition that would, in the investigator's judgment, interfere with full participation in the study, including administration of study treatment and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.
- •Participants who are known to be HIV-positive.
- •For Group C ,D and E : History or presence of an abnormal ECG that in the investigator's opinion, is clinically meaningful. Average QTc interval > 480 milliseconds is excluded (corrected by Fridericia or Bazett formula).
- •History of a gastrointestinal condition (eg, inflammatory bowel disease, Crohn's disease, ulcerative colitis) that may affect oral drug absorption.
- •Exclusion criteria specific to a group receiving combination therapy. a. Participants enrolled in the epacadostat combination (Groups C and E only) b. Participants enrolled in the pemigatinib combination (Group D only)
- •Has disease eligible for potentially curative treatment with standard chemotherapy, surgical resection, or chemoradiotherapy.
- •The following participants are excluded in France: vulnerable populations according to article L.1121-6 of the French Public Health Code and adults under legal protection, or who are unable to express their consent per article L.1121-8 of the French Public Health Code, not affiliated to a social security per article L.1121-8-1 of the French Public Health Code.
- •Receipt of anticancer therapy within 28 days of the first administration of study treatment, with the exception of localized radiotherapy.
- •Toxicity of prior therapy that has not recovered to ≤ Grade 1 (withthe exception of alopecia and anemia not requiring transfusional support), unless approved by the medical monitor.
- •Groups C ,D and F (combinations): Immune-related toxicity during prior checkpoint inhibitor therapy for which permanent discontinuation of therapy is recommended (per product label or consensus guidelines), OR severe immune-related toxicity requiring intensive (eg, use of infliximab) or prolonged immunosuppression (eg, > 6 weeks) to manage (with the exception of endocrinopathy that is well-controlled on replacement hormones).
- •Group F only: Previous treatment with LAG-3 or TIM-3 directed therapy or lenvatinib.
- •Group F only: Participants with multiple metastases that achieved mixed tumor response to prior anti–PD-(L)1 therapy (such as isolated progressive lesion in a context of PR/CR or SD for other lesions) or achieved overall disease progression based only on a single new lesion.
- •Participant with laboratory values at screening defined in Table 8
研究组 & 干预措施
INCAGN02390
Test
干预措施: INCAGN02390 (Drug)
Retifanlimab (INCMGA00012)
Test
干预措施: Retifanlimab (INCMGA00012) (Drug)
Pemazyre 4.5 mg tablets
Test
干预措施: Pemazyre 4.5 mg tablets (Drug)
INCAGN02385
Test
干预措施: INCAGN02385 (Drug)
结局指标
主要结局
Group A (INCMGA00012 monotherapy): ORR, defined as the proportion of participants having a CR or PR according to RECIST v1.1, will be determined by ICR.
Group A (INCMGA00012 monotherapy): ORR, defined as the proportion of participants having a CR or PR according to RECIST v1.1, will be determined by ICR.
次要结局
- Group A and B (INCMGA00012 monotherapy): DOR, defined as the time from the first documented objective response (CR or PR) according to RECIST v1.1 (as determined by ICR) until disease progression or death due to any cause
- Group A and B (INCMGA00012 monotherapy): DCR, defined as the proportion of participants with CR, PR, or SD (as determined by ICR) as best response.
- Group A and B (INCMGA00012 monotherapy): PFS, defined as the time from the first dose of study treatment until disease progression (as determined by ICR) or death due to any cause.
- Group A and B (INCMGA00012 monotherapy): OS, defined as the time from the first dose of study treatment until death due to any cause.
- All other groups: • ORR, defined as the proportion of participants having a CR or PR according to RECIST v1.1 (as determined by the investigator). Safety and tolerability will be assessed by monitoring the frequency and severity of AEs and SAEs as well as laboratory test results.
研究者
Clinical Trial Information
Scientific
Incyte Corp.
研究点 (24)
Loading locations...
相似试验
招募中
3 期
A Randomized, Double Blind, Phase 3 Study of Platinum-Based Chemotherapy With or Without INCMGA00012 in First-Line Metastatic Squamous and Nonsquamous Non–Small Cell Lung Cancer (POD1UM-304)2022-501987-16-00Incyte Corp.14
进行中（未招募）
1/2 期
DESTINY-Breast07 will investigate the safety, tolerability, and anti-tumour activity of trastuzumab deruxtecan (T-DXd) in combination with other anticancer agents in patients with HER2-positive Metastatic Breast Cancer inclusive of patients with active and stable brain metastases2023-505309-18-00AstraZeneca AB46
招募中
3 期
A Phase 3 Single-Arm Study of UGN-102 for Treatment of LG IR NMIBC2023-506680-34-00Urogen Pharma Ltd.161
尚未招募
1 期
Study of TYK-01054 Capsules in Patients With Advanced Solid TumorsNCT07282873TYK Medicines, Inc219
招募中
1 期
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous Administration in Healthy Adult ParticipantsNCT07448155Incyte Corporation126